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CRC

:   colorectal cancer

XELOX

:   capecitabine and oxaliplatin

DCR

:   disease control rate

RR

:   objective tumor response rate

PFS

:   progression‐free survival

OS

:   overall survival

CR

:   complete response

PR

:   partial response

CI

:   confidence interval

1. INTRODUCTION {#ags312023-sec-0005}
===============

The National Comprehensive Cancer Network recommends that patients with metastatic colorectal cancer (CRC) undergo primary tumor resection if they have impending obstruction, bowel obstruction, or potentially resectable metastases. There is no doubt that resection or stoma placement is mandatory before starting systemic chemotherapy among patients with severe intestinal symptoms.[1](#ags312023-bib-0001){ref-type="ref"}, [2](#ags312023-bib-0002){ref-type="ref"}, [3](#ags312023-bib-0003){ref-type="ref"} Palliative resection of primary tumors reportedly improves systemic chemotherapy efficacy[4](#ags312023-bib-0004){ref-type="ref"} and prolongs time to treatment failure.[5](#ags312023-bib-0005){ref-type="ref"} In many cases, it is not possible for patients to continue chemotherapy because of complications, such as bleeding, perforation and bowel obstruction, if chemotherapy is started without surgical resection of the symptomatic primary tumor. Therefore, surgical resection of the primary tumor is apparently necessary to utilize chemotherapy with few complications. However, surgical resection may delay chemotherapy initiation.[6](#ags312023-bib-0006){ref-type="ref"} In general, a post‐surgical period longer than 4 weeks is standard until starting chemotherapy,[6](#ags312023-bib-0006){ref-type="ref"}, [7](#ags312023-bib-0007){ref-type="ref"} such as treatment with folinic acid, fluorouracil (5‐FU), and oxaliplatin; folinic acid, 5‐FU, and irinotecan; and capecitabine and oxaliplatin (XELOX). However, there is no positive evidence for this delay. In stage III disease, the time to start adjuvant therapy is an important prognostic factor for both colon and rectal cancers.[8](#ags312023-bib-0008){ref-type="ref"}, [9](#ags312023-bib-0009){ref-type="ref"}, [10](#ags312023-bib-0010){ref-type="ref"}, [11](#ags312023-bib-0011){ref-type="ref"} Early adjuvant therapy initiation is most often defined as starting therapy within 8 weeks after surgery, and it reportedly reduces the risks of recurrence and increases overall survival (OS) and disease‐free survival.[8](#ags312023-bib-0008){ref-type="ref"}, [9](#ags312023-bib-0009){ref-type="ref"} Metastatic tumors may rapidly enlarge before starting chemotherapy and may lead to patient death. It is unclear whether an even earlier initiation, such as within 1 week after surgery, may provide additional improvements. We conducted a clinical trial to prevent the early growth of metastatic lesions after primary resection. Because we previously reported that early initiation of chemotherapy after surgery is feasible,[12](#ags312023-bib-0012){ref-type="ref"} we evaluated its efficacy in patients subjected to colorectal surgery for symptomatic (narrowing of the stool, constipation, rectal bleeding, abdominal pain etc.) CRC with synchronous multiple distant metastases.

2. MATERIALS AND METHODS {#ags312023-sec-0006}
========================

2.1. Study design {#ags312023-sec-0007}
-----------------

Pearl Star 02 was a prospective, open‐label, single‐arm phase II trial that was completed in Japan. This study was carried out according to the ethical guidelines for clinical studies. The institutional review board at the Fukuoka University approved the protocol, and the study has been registered with the University Hospital Medical Information Network Clinical Trials Registry (ID: UMIN000006310).

This study evaluated the efficacy of early initiation of chemotherapy after resecting colorectal cancer with distant metastases. Primary endpoint was disease control rate (DCR), whereas secondary endpoints were objective tumor response rate (RR), progression‐free survival (PFS), overall survival (OS), and safety. The target sample size was 18 patients, assuming that the expected DCR and threshold DCR were 95% and 75%, respectively, with a one‐sided alpha level of 5% and a power of 80%. The expected DCR was decided based on past experience of the Pearl Star 01 trial at our hospital.[12](#ags312023-bib-0012){ref-type="ref"}

2.2. Patients and eligibility criteria {#ags312023-sec-0008}
--------------------------------------

In the present study, 20 patients were enrolled between September 2011 and June 2015. Eligibility criteria for selecting subjects were as follows: (i) age 20‐75 years; (ii) Eastern Cooperative Oncology Group performance status of 0 or 1; (iii) histologically confirmed CRC without prior chemo‐ or radiotherapy for metastatic disease; (iv) unresectable synchronous distant metastases; (v) adequate hematological (absolute leukocyte count, 4000‐12 000 leukocytes/mm^3^; neutrophil count, ≥1500 neutrophils/mm^3^; and platelet count, ≥100 000 platelets/mm^3^), hepatic (transaminase level, ≤100 IU/L and serum bilirubin level, ≤2.0 mg/dL), and renal (serum creatinine level, female: ≤1.35 mg/dL, male: ≤1.8 mg/dL) function; (vi) ability to take oral medications; and (vii) primary tumor resection 7 days before start of chemotherapy. Written informed consent was obtained from each patient.

Patients with any of the following conditions were excluded: history of serious hypersensitivity to drugs, active infection, symptomatic brain metastases, uncontrolled hypertension, uncontrolled diabetes, cirrhosis, clinically significant cardiovascular disease, history of myocardial infarction within the previous 3 months, uncontrolled angina pectoris or arrhythmia, multiple primary cancers within the past 5 years, pleural effusion requiring drainage, ascites or pericardial effusion, clinically significant mental or psychological disease, or any other condition that made the patient unsuitable for this study.

2.3. Treatment {#ags312023-sec-0009}
--------------

Patients underwent XELOX therapy (130 mg/m^2^ oxaliplatin on day 1+1000 mg/m^2^ capecitabine twice daily on days 1‐14) on postoperative day 7 and XELOX+bevacizumab (7.5 mg/kg bevacizumab and 130 mg/m^2^ oxaliplatin on day 1+1000 mg/m^2^ capecitabine twice daily on days 1‐14, every 3 weeks) after the second chemotherapy cycle.[13](#ags312023-bib-0013){ref-type="ref"}, [14](#ags312023-bib-0014){ref-type="ref"} Dose reductions were required for all grade 3 or 4 toxicities that were attributed to the study medications. Treatment was continued until disease progression, unacceptable toxicities, or withdrawal of consent. Study treatment was delayed if any of the following criteria were applicable within 1 day of scheduled administration: neutrophil count, \<1000/mm^3^; platelet count, \<75 000/mm^3^; active infection with fever ≥38.0°C; grade 2 or worse diarrhea; grade 3 or worse peripheral sensory neurophathy (PSN); or other grade 2 or worse non‐hematological toxicities. Oxaliplatin dose was reduced to 100 mg/m^2^ if grade 3‐4 neutropenia or thrombocytopenia, persistent grade 2 or reversible grade 3 PSN, or any grade 3‐4 non‐hematological toxicities occurred. The patient was removed from the study if grade 3 toxicity persisted after a 21‐day washout period or if grade 4 PSN or grade 2‐4 allergic reaction occurred. The patient was also removed from the study if the patient required \>3 weeks to recover from an adverse event.

2.4. Evaluation of chemotherapy {#ags312023-sec-0010}
-------------------------------

All patients underwent physical examination, chest radiography, and computed tomography of the abdomen, pelvis, and chest before start of treatment. All patients were included in the safety and efficacy analyses. Severity of adverse events was evaluated according to the National Cancer Institute Common Toxicity Criteria, version 4.0. Tumors were measured at 6‐ to 8‐week intervals, and responses were evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Evaluation of responses was based on radiologist‐reported measurements. Complete and partial responses required subsequent confirmation after an interval of at least 4 weeks. DCR was calculated from the number of patients who had a complete response (CR), partial response (PR), or stable disease with treatment, whereas RR was based on the number of patients who had either CR or PR. Progression was defined as objective tumor progression or death from any cause and was calculated using the Kaplan‐Meier method. PFS was calculated based on the date of study entry until progression or death. OS was calculated from the date of study entry until death from any cause and was calculated using the Kaplan‐Meier method. All calculations were carried out using SPSS IBM v. 23 (IBM, Chicago, IL, USA).

3. RESULTS {#ags312023-sec-0011}
==========

3.1. Baseline patient characteristics {#ags312023-sec-0012}
-------------------------------------

Characteristics of the study patients are presented in Table [1](#ags312023-tbl-0001){ref-type="table-wrap"}. Twenty‐three patients fulfilled the inclusion criteria before surgery and three patients were excluded because of complications during the study period. No patients rejected informed consent. Baseline characteristics of the 15 male and five female participants included a median age of 64 (range, 43‐72) years. Eastern Cooperative Oncology Group (ECOG) performance status scores were 0 and 1 in 90.0% and 10.0% of patients, respectively. There was no emergency surgery. Right hemicolectomy was carried out in six patients, sigmoidectomy in three, anterior resection without stoma in five, and Hartmann procedure in six. Median operating time was 135 (range, 75‐292) min, and estimated blood loss was 98 (range, 5‐520) mL. Median follow‐up time was 24.3 months (range, 8.4 months to 44.0 months).

###### 

Baseline characteristics of patients with colorectal cancer with distant metastases (N=20)

                            N (%)       Median   Range
  ------------------------- ----------- -------- --------
  Age, years                            64       43‐72
  Gender                                         
  Male                      15 (75.0)            
  Female                    5 (25.0)             
  ECOG Performance Status                        
  0                         18 (90.0)            
  1                         2 (10.0)             
  Primary cancer                                 
  Colon                     11 (55.0)            
  Rectum                    9 (45.0)             
  Metastatic site                                
  Liver                     18 (90.0)            
  Lung                      9 (45.0)             
  Peritoneum                4 (20.0)             
  Bone                      1 (5.0)              
  Operation                                      
  Time (min)                            135      75‐292
  Bleeding (mL)                         98       5‐520
  Stoma (+)                 6 (30)               
  Stoma (−)                 14 (70)              

ECOG, Eastern Cooperative Oncology Group.
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3.2. Treatment {#ags312023-sec-0013}
--------------

All patients successfully started chemotherapy on postoperative day 7 (Figure [1](#ags312023-fig-0001){ref-type="fig"}). Median number of chemotherapy cycles was 14 (range, 4‐30). Median cumulative dose of oxaliplatin was 1751 mg/m^2^. Fifteen patients (75.0%) continued treatment for more than eight cycles, whereas three discontinued treatment for adverse events and two discontinued treatment because of refusal or personal reasons. Four patients (20.0%) required dose reduction at least once within the eight cycles: two because of fatigue, one as a result of diarrhea, and one owing to thrombocytopenia.

![Flowchart of patients in the present study.](AGS3-1-219-g001){#ags312023-fig-0001}

3.3. Efficacy {#ags312023-sec-0014}
-------------

Confirmed response rate was 80.0% (95% confidence interval \[CI\], 56.3‐94.3) (CR, 0%; PR, 80.0%; stable disease, 20.0%; and progressive disease, 0%). DCR was 100%. PFS ranged from 5.5 to 38.2 months with a median of 14.9 months. OS was 26.3 months (Figure [2](#ags312023-fig-0002){ref-type="fig"}).

![Kaplan‐Meier survival curves. (A) Progression‐free survival and (B) overall survival.](AGS3-1-219-g002){#ags312023-fig-0002}

3.4. Safety {#ags312023-sec-0015}
-----------

Adverse events for 20 patients are summarized in Table [2](#ags312023-tbl-0002){ref-type="table-wrap"}. During the postoperative period, postoperative complications were observed in two patients (superficial incisional surgical site infection \[Clavien‐Dindo grade I\] and ileus \[Clavien‐Dindo grade I\]). However, no patient developed complications because of starting chemotherapy, and no in‐hospital mortality occurred. One patient developed grade 2 thrombocytopenia. Grade 1 hand‐foot syndrome was observed in 65% of patients. Grade 3‐4 non‐hematological adverse events were reported in five patients.

###### 

Hematological/non‐hematological adverse events and postoperative complications

  Hematological grade 3‐4                  Non‐hematological grade 3‐4
  ---------------------------------------- -----------------------------
  5.0%                                     25.0%
  Thrombocytopenia: 1                      Fatigue: 2
  Diarrhea: 1                              
  Pneumonia: 1                             
  Ileus: 1                                 
  Postoperative complications              
  Superficial surgical site infection: 1   
  Ileus: 1                                 

John Wiley & Sons, Ltd

4. DISCUSSION {#ags312023-sec-0016}
=============

Surgical intervention has been suspected to promote cancer growth since ancient times but has received little attention from clinicians.[17](#ags312023-bib-0017){ref-type="ref"} Upfront primary tumor resection significantly increases the risk of progression for synchronous colorectal liver metastases as confirmed in a multivariate analysis.[18](#ags312023-bib-0018){ref-type="ref"}, [19](#ags312023-bib-0019){ref-type="ref"} Recent studies into the biology of metastasis formation and the tumor‐host relationship have added weight to the hypothesis of treatment‐induced stimulation of cancer growth and dissemination. The primary tumor and distant metastases are communicating ecosystems, which are characterized by a diversity of host cells that are both recruited from the bone marrow and locally.[20](#ags312023-bib-0020){ref-type="ref"} The ecosystems are also elucidated by the diversity of biological pathways responsible for the communication of the tumor cells with each of the host cells.[21](#ags312023-bib-0021){ref-type="ref"}, [22](#ags312023-bib-0022){ref-type="ref"}

Plasma angiopoietin‐2 and vascular endothelial growth factor (VEGF) levels are significantly raised after CRC surgery.[23](#ags312023-bib-0023){ref-type="ref"} Peak levels were observed during days 7‐13 after surgery. The same researchers described that CRC surgery is linked to a persistent elevation in vascular cell adhesion molecule 1 (VCAM‐1) levels during the first month after surgery. VCAM‐1 may promote angiogenesis and chemotaxis of endothelial cells.[24](#ags312023-bib-0024){ref-type="ref"} Peeters et al.[25](#ags312023-bib-0025){ref-type="ref"} observed that metastasis growth is accompanied by increased cell proliferation and a significant decrease in the fraction of apoptotic cells on serial biopsies after resecting the primary tumor. The same researchers found significantly elevated cancer activity in liver metastases from CRC as measured by fluorodeoxyglucose‐positron emission tomography (FDG‐PET) after primary tumor resection.[18](#ags312023-bib-0018){ref-type="ref"}

The precise timing for starting chemotherapy prior to and/or after surgery to avoid postoperative complications is unclear, but an interval of at least 4 weeks has been proposed. In most clinical trials, patients who underwent an operation within 4 weeks were excluded. We reported a case involving the early initiation of chemotherapy on postoperative day 7 who had undergone right hemicolectomy for synchronous multiple liver, lung, and peritoneal metastases.[26](#ags312023-bib-0026){ref-type="ref"} He survived without postoperative complications for 22 months despite huge liver metastases. Therefore, we carried out the present pilot study to confirm the feasibility of an immediate start for chemotherapy after surgery.[12](#ags312023-bib-0012){ref-type="ref"}

Giving early postoperative 5‐FU has been investigated to improve outcomes after resecting intestinal malignancies.[27](#ags312023-bib-0027){ref-type="ref"} Surgeons have been reluctant to prescribe 5‐FU in the immediate postoperative period. This has primarily been associated with the belief that 5‐FU increases anastomotic leak rate, which could result in the need for reoperation, creation of a colostomy, need for a future takedown of colostomy, or even death. It has been estimated that one of every three postoperative deaths after colonic surgery was because of a leaking anastomosis.[28](#ags312023-bib-0028){ref-type="ref"} Several animal researchers have revealed that anastomoses were weaker and that there was a high risk of anastomotic leakage when systemic 5‐FU was given as a bolus immediately after surgery.[29](#ags312023-bib-0029){ref-type="ref"}, [30](#ags312023-bib-0030){ref-type="ref"} Immediate i.p. 5‐FU also causes anastomotic leakage.[31](#ags312023-bib-0031){ref-type="ref"} Continuous 5‐FU infusions enabled the use of greater daily dosages and appeared safer than injecting a bolus of 5‐FU.[32](#ags312023-bib-0032){ref-type="ref"} Continuous infusion avoided the high serum 5‐FU levels that could be observed with bolus injection dosage and may be efficacious in CRC without increasing anastomotic leakage. The oral fluoropyrimidine drug, capecitabine, evolved to ameliorate patient convenience and tolerability and has replaced continuous infusions of 5‐FU in many chemotherapy regimens.[33](#ags312023-bib-0033){ref-type="ref"} Capecitabine appears to be a promising substitute to continuous infusions of 5‐FU, and pharmacokinetic researchers have reported that successive oral administration provided a steady‐state 5‐FU concentration that was comparable with that achieved by a 5 day continuous infusion.[34](#ags312023-bib-0034){ref-type="ref"}, [35](#ags312023-bib-0035){ref-type="ref"} Furthermore, bolus 5‐FU treatments led to extremely high concentrations, followed by rapid disappearance from the blood serum.[34](#ags312023-bib-0034){ref-type="ref"}, [35](#ags312023-bib-0035){ref-type="ref"} Therefore, we chose XELOX therapy for the present study. Regarding safety, grade 3‐4 fatigue was observed in 10% of patients in this study. However, this result was more frequent than the 1‐3% of the SOFT study[36](#ags312023-bib-0036){ref-type="ref"} and the 4‐6% of the WJOG 4407G study.[37](#ags312023-bib-0037){ref-type="ref"} The reason may be because of synchronous metastases, early chemotherapy initiation, or adverse events of primary tumor resection.

According to recent reports,^38--50^ OS of patients with CRC and synchronous distant metastases was 11--21 months, whereas the previously reported PFS had ranged from 5.1 to 10.5 months (Table [3](#ags312023-tbl-0003){ref-type="table-wrap"}). Although our study cannot be compared with large multicenter trials, OS and PFS from this study were better than those from other studies. Therefore, early chemotherapy initiation after CRC surgery may prevent tumor growth. However, the results were obtained from the comparison with past reports using different regimens. This is a critical point for understanding the effect of early initiation of chemotherapy. Randomized controlled trials are considered essential to confirm the result. The primary CRC resection causing bleeding and severe stenosis is the first treatment step to prevent complications related to CRC. According to the Cochrane review, primary tumor resection is not associated with a consistent improvement in OS and fails to significantly reduce the risk of complications from the asymptomatic primary tumor[51](#ags312023-bib-0051){ref-type="ref"}. However, our study enrolled symptomatic patients with CRC. The results will help identify answers and perform advanced trials.

###### 

Comparison with other studies: Primary tumor resection with synchronous metastases

  Author                                                    Year   No. patients   Chemotherapy                                 PFS (95% CI)       OS (95% CI)
  --------------------------------------------------------- ------ -------------- -------------------------------------------- ------------------ ------------------
  Tebutt et al.[38](#ags312023-bib-0038){ref-type="ref"}    2003   280            5‐FU/raltitrexed+capecitabine                NA                 14.0
  Ruo et al.[39](#ags312023-bib-0039){ref-type="ref"}       2003   127            NA                                           NA                 16
  Cook et al.[40](#ags312023-bib-0040){ref-type="ref"}      2005   17658          NA                                           NA                 Colon: 11
                                                                                                                                                  Rectum: 16
  Koopman et al.[41](#ags312023-bib-0041){ref-type="ref"}   2007   258            Capecitabine/XELIRI                          6.7                16.7
  Galizia et al.[42](#ags312023-bib-0042){ref-type="ref"}   2008   42             5‐FU±oxaliplatin/irinotecan                  NA                 17
  Tol et al.[43](#ags312023-bib-0043){ref-type="ref"}       2008   289            XELOX+bevacizumab+cetuximab                  10.5               20.7
  Bajwa et al.[44](#ags312023-bib-0044){ref-type="ref"}     2009   32             5FU+oxaliplatin/5FU+oxaliplatin+irinotecan   NA                 14
  Evans et al.[45](#ags312023-bib-0045){ref-type="ref"}     2009   45             NA                                           NA                 11
  Ferrand et al.[46](#ags312023-bib-0046){ref-type="ref"}   2013   156            LV5FU2/pi5FU/raltitrexed                     5.1 (4.6‐5.6)      16.3 (13.7‐19.2)
  Ahmed et al.[47](#ags312023-bib-0047){ref-type="ref"}     2014   761            5‐FU±oxaliplatin/irinotecan                  NA                 15.2
  Tsang et al.[48](#ags312023-bib-0048){ref-type="ref"}     2014   8599           NA                                           NA                 21
  Faron et al.[49](#ags312023-bib-0049){ref-type="ref"}     2015   478            NA                                           NA                 19.2 (18.2‐20.4)
  Xu et al.[50](#ags312023-bib-0050){ref-type="ref"}        2015   44514          NA                                           NA                 16 (15.7‐16.3)
  Present study                                             2016   20             XELOX+bevacizumab                            14.9 (11.4‐18.4)   26.3 (20.6‐31.9)

CI, confidence interval; NA, not available; OS, overall survival; PFS, progression‐free survival.

John Wiley & Sons, Ltd

To the best of our knowledge, this was the first report to determine the safety and efficacy of an early initiation of chemotherapy after resecting a primary CRC with distant synchronous metastases. Early initiation of chemotherapy after surgery may improve the prognosis of patients with CRC having synchronous metastases. Limitations include small numbers of patients and the nonrandomized study. Furthermore, this study included six patients without anastomosis Hartmann procedures. They were one‐third of all patients that was not small portion. Written informed consent was obtained from each patient on the 5^th^ postoperative day. Patients who had no postoperative complication were selected. Therefore, there is a risk for a considerable bias that we selected patients in an otherwise perfect state of health. Although we have shown that it was feasible to start chemotherapy a week after surgery, the actually benefit of this is uncertain. Randomized controlled trials will be essential to validate these findings. We might need more patients to clarify it.
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